<div id="readability-page-1"><div>Zalevsky Jonathan Vice President of Nektar Therapeutics [NKTR] filed a Form 4 on November 25, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>11/21/25</td><td>Exercise</td><td>2,666</td><td>$0.00</td><td>N/A</td></tr><tr><td>11/25/25</td><td>Surrender(1)</td><td>1,157</td><td>$54.28</td><td>$62,802</td></tr></tbody></table></div>Ending Holdings: 18,971 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

NKTR

Jonathan Zalevsky, Vice President of Nektar Therapeutics, filed a Form 4 with the SEC on November 25, 2025, disclosing changes in ownership. He exercised 2,666 shares and surrendered 1,157 shares at $54.28 each to cover option exercise costs and/or tax liabilities. His ending holdings are 18,971 shares directly. This transaction is part of insider trading activities.

VP Zalevsky Acquires 1,509 Of Nektar Therapeutics [NKTR]